Why the study?
Platelet aggregation and neuronal injury are central factors in ischemic stroke, creating a need for dual-acting drugs with both antiplatelet and neuroprotective effects.
The lipid nanocrystal formulation TJ94@LNC presents a promising intravenous nanoplatform that overcomes brain delivery challenges to synergistically provide antiplatelet and neuroprotective therapy for ischemic stroke.
Answers are grounded in this paper and cite their sources.
May support dual therapy for ischemic stroke; leaves open clinical translation of TJ94@LNC.
Platelet aggregation and neuronal injury are central factors underlying the pathogenesis of ischemic stroke (IS), thus dual-acting drugs possessing both antiplatelet and neuroprotective effects are highly needed. We synthesized a novel dual-action drug-TJ94 for neuroprotective and anti-platelet action in IS. To facilitate intravenous administration of TJ94, we developed a lipid nanocrystal formulation (TJ94@LNC) to increase the solubility, brain accumulation and therapeutic of TJ94 effects on IS. Our results clearly indicated that TJ94@LNC has great potential in brain accumulation due to the enrichment of transferrin (Tf) and apolipoprotein A1 (ApoA1) in the protein corona, which might improve the therapeutic effects of TJ94 on middle cerebral artery occlusion/reperfusion (MCAO/R) rats in both the acute and chronic phase of IS. Consistent with the design of TJ94, its therapeutic effects are attributed to its neuroprotective properties, which include inhibiting oxidative stress and apoptosis, as well as its antiplatelet activity. This lipid nanocrystal nanoplatform effectively addresses the brain delivery challenges of TJ94 to synergistically exert dual-functional therapeutic effects. It provides an effective solution for the intravenous injection of lipid-soluble drugs for the treatment of IS. This research presents TJ94@LNC as a promising therapeutic nanoplatform for IS. Lipid nanocrystal nanoplatform effectively addresses the brain delivery challenges of TJ94 to synergistically exert dual-functional therapeutic effects, which improved the neuroprotective and anti-platelet effects of TJ94 on middle cerebral artery occlusion/reperfusion (MCAO/R) rats in both the acute and chronic phase of ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: